Development of PET Radioligands Targeting COX-2 for Colorectal Cancer Staging, a Review of in vitro and Preclinical Imaging Studies

Frontiers in Medicine

Michel Chérel¹  Yann Touchefeu²  Frédéric Buron³  Sylvain Routier³  François Avry⁴  Caroline Dagallier⁵  Nicolas Arlicot⁶ 

[1] CRCINA, INSERM, CNRS, Nantes University, Nantes, France;CRCINA, INSERM, CNRS, Nantes University, Nantes, France;Institut des Maladies de l'Appareil Digestif, University Hospital, Nantes, France;ICOA, Université d'Orléans, UMR CNRS 7311, Orléans, France;Inserm UMR1253, iBrain, Université de Tours, Tours, France;Unité de Radiopharmacie, CHRU de Tours, Tours, France;Inserm UMR1253, iBrain, Université de Tours, Tours, France;Unité de Radiopharmacie, CHRU de Tours, Tours, France;Inserm UMR1253, iBrain, Université de Tours, Tours, France;INSERM CIC 1415, CHRU de Tours, Tours, France;

关键词: COX-2;    PET;    colorectal cancer;    radioligands;    preclinical model;   

DOI  :  10.3389/fmed.2021.675209

来源: Frontiers

【 摘 要 】

Colorectal cancer (CRC) is the second most common cause of cancer death, making early diagnosis a major public health challenge. The role of inflammation in tumorigenesis has been extensively explored, and among the identified markers of inflammation, cyclooxygenase-2 (COX-2) expression seems to be linked to lesions with a poor prognosis. Until now, COX-2 expression could only be accessed by invasive methods, mainly by biopsy. Imaging techniques such as functional Positron Emission Tomography (PET) could give access to in vivo COX-2 expression. This could make the staging of the disease more accurate and would be of particular interest in the exploration of the first metastatic stages. In this paper, we review recent progress in the development of COX-2 specific PET tracers by comparing the radioligands' characteristics and highlighting the obstacles that remain to be overcome in order to achieve the clinical development of such a radiotracer, and its evaluation in the management of CRC.

【 授权许可】

CC BY